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Abstract
In this paper, we present a full review of the present guidelines on antiplatelet properties and indications for the prophy-
lactic usage of acetylsalicylic acid (ASA). We include the results of the latest research mainly on primary prevention, the 
optimal dosage in the context of ASA resistance, and the possibilities of long-term co-operation with patients requiring 
ASA administration. We also discuss prevention methods of frequently occurring gastrointestinal symptoms of drug 
intolerance.
Key words: ASA, atherosclerosis, pharmacotherapy, ischaemic heart disease, safety profile
Folia Cardiologica 2019; 14, 5: 475–482
History of medical uses  
of acetylsalicylic acid
Drugs that belong to salicylates are as old as medicine. The 
analgesic, antipyretic and anti-inflammatory properties of 
willow bark were already known in distant antiquity: the 
oldest references appear on Sumerian stone tablets from 
around 2000 B.C. The Ebers Papyrus (around 1550 B.C.) 
is another proof that the benefits of salicylates were under-
stood. Similarly, most of those sometimes referred to as 
the ‘Fathers of Medicine’ recommended the use of willow 
extract for medicinal purposes, including Hippocrates, 
Celsus, Pedanios Dioskurydes, Pliny the Elder, and Galen. 
The status quo did not change much until the 18th century, 
when Reverend Edward Stone described the unusual ef-
fects of willow bark in the treatment of fever associated with 
malaria symptoms, comparing it to the applied Jesuit bark 
(it is now known that it was rich in quinine). He presented 
the results of his research in 1763 to a meeting of the Royal 
Society, which led to plants rich in salicylates becoming 
a cheaper substitute for antimalarial preparations.
The nineteenth century brought identification of the 
active substance found in willow bark: in 1828, Joseph 
Buchner isolated salicin crystals. Ten years later, Raffaele 
Piria discovered a method of even more effective salicylic 
acid extraction. The following years brought increasing 
knowledge about the characteristics of salicylates usage, 
and also about their side effects, with gastric irritation to 
the fore. In 1897, Felix Hoffman was inspired by the side 
effects of sodium salicylate experienced by his father who 
had been prescribed it as part of rheumatism treatment. 
Hoffman developed an efficient method of producing its 
derivative, acetylsalicylic acid (ASA), which after acetylation 
gained valuable properties of heart disease prevention, as 
is known nowadays. Initial studies were difficult because 
of suspected heart damage. Finally, the drug patent was 
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granted to Bayer, and since 1899 ASA has been available 
under the trade name Aspirin®, which was later recognised 
as the equivalent of the chemical name.
The first reports of the potential impact of ASA on the 
cardiovascular system in the form of a reduced number 
of cardiovascular incidents did not appear until 1950. 
A breakthrough discovery in this regard was made by 
an American doctor, Lawrence L. Craven, who observed 
an increased risk of bleeding in patients taking ASA as 
a painkiller and hypothesised that it was an anticoagu-
lant and may lower the risk of coronary thrombosis and 
heart attack. His observational studies, however, did not 
gain widespread acceptance, and incidentally Dr Craven 
himself died of a heart attack. It was not until the 1980s 
that the world of medicine accepted the effectiveness of 
ASA in counteracting arterial thromboembolic events: in 
1988, the American Food and Drug Administration (FDA) 
recognised secondary prevention of myocardial infarction 
as an indication for ASA.
Mechanism of action and dosage of ASA
Acetylsalicylic acid is a non-steroidal anti-inflammatory 
drug (NSAID), showing anti-inflammatory, antipyretic, anal-
gesic and antiaggregatory effects. The basic mechanism of 
action is acetylation of the hydroxyl group of serine located 
in the active site of cyclooxygenase (COX, cyclooxygenase), 
which leads to irreversible inactivation of the enzyme by 
preventing its association with arachidonic acid. Cyclooxy-
genase occurs in two forms: COX-1, present mainly in 
platelets, is largely responsible for the production of throm-
boxane, while COX-2 (common in nucleated cells, including 
endothelium) is largely responsible for the production 
of anticoagulant and pro-inflammatory prostaglandins. 
The ability of ASA to acetylate serine in both COX-1 and 
COX-2 is the explanation of its broad spectrum of activity. 
A lack of COX activity significantly reduces the number of 
emerging intra- and extracellular mediators, which include 
prostaglandins, prostacyclins and thromboxanes. Reducing 
the formation of prostanoids suppresses inflammation, 
and thromboxane inhibits platelet aggregation, making it 
difficult to form clots.
Importantly, ASA inhibits COX-1 almost 200 times more 
strongly than it does COX-2. This means that the expected 
anti-platelet effect can be achieved with a much lower dose 
than is necessary to achieve the anti-inflammatory effect. 
This reduces the risk of side effects (dose-dependent) 
and allows a patient to take small, anti-platelet doses over 
a long period.
ASA has an antiplatelet effect already at doses of about 
50 mg (in the case of chronic use even as little as 20 mg), 
but higher doses cause a more predictable and faster re-
sponse (in healthy people, after taking an 80 mg dose the 
full effect takes 15–30 minutes). This justifies their use, for 
example, as the first dose in a heart attack. Restoration of 
the thrombotic potential of platelets is therefore possible 
by renewing the thrombocyte population (living for about 
10 days) not affected by ASA.
Views on the correct dose of ASA as an antiplatelet 
drug remain surprisingly diverse. In most European coun-
tries, including Germany, Austria, France, Spain, Belgium 
and Portugal, the usual dose is 100 mg/day. In the United 
States, the most preferred dose is 81 mg, while stressing 
that the 75 mg/day dose seems too low for an adult. 
In Australia, the dose range is from 75 up to 150 mg, 
however the most commonly chosen is 100 mg/day. The 
most commonly prescribed dose in Poland, 75 mg/day, 
is equally often used in principle only in Great Britain. 
Although doses from 75 mg/day are usually mentioned as 
antiplatelet agents, a 100 mg ASA tablet appears on the 
list of ‘essential medicines’ published by the World Health 
Organisation (WHO) [1].
An attempt to resolve dosage controversies have resul-
ted in a systematic review and meta-analysis that compared 
11 randomised trials involving a total of 104,101 patients 
with a median follow-up of 60 months [2]. The range of 
doses tested was significant: from 50 mg/day to as much 
as 990 mg/day, but no significant strong differentiation of 
the preventive effect was found depending on the dose. 
Subtle trends were noted when broken down into doses: 
100 mg/day (better indicators regarding the risk of death, 
cancer death, cancer and major gastrointestinal bleeding); 
over 100 mg/day (stronger cardiovascular protection); 
no more than 100 mg/day (better tolerance, lower risk 
of intracranial bleeding). Therefore, it seems sensible to 
consider that in order to provide full protection, the dose 
should be maximised, while avoiding an ineffective increase 
above the 100 mg/day threshold. In a recent meta-analysis, 
insufficient preventive efficacy of the lowest doses in pa-
tients with higher (> 70–80 kg) body weight was suggested 
[3]. This is in line with analysis of the authors of this paper 
regarding of risk factors for ASA resistance (see below). 
An increased rate of thrombocyte renewal is observed in 
diabetes mellitus; data suggests a greater efficacy of ASA 
administered twice a day.
Indications for use of ASA  
according to current guidelines
ASA has revolutionised modern medicine to a degree com-
parable to penicillin, becoming one of the most important 
drugs of the 20th century. Its primary use is secondary 
prevention of cardiovascular diseases i.e. thrombotic 
complications of atherosclerosis. The effect of ASA on 
venous thrombosis (reduction of relapses by more than 
25%; ASPIRE study) or intracardiac (in atrial fibrillation) is 
weaker than that of drugs that inhibit the plasma system. 
A separate issue, and the subject of some controversy, is 
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the preventive effect of ASA on the formation of cancers, 
especially of the large intestine.
The 2016 guidelines of the European Society of Car-
diology (ESC) on the prevention of cardiovascular diseases 
[4] clearly highlight the key role of ASA in the treatment of 
patients as part of secondary prevention, with clinically 
confirmed coronary artery disease, history of ischaemic 
or symptomatic stroke, and atherosclerosis of peripheral 
arteries. The starting point was the prospective, blinded 
SAPAT (Swedish Angina Pectoris Aspirin Trial) study, which 
demonstrated a 34% reduction in the risk of a complex 
endpoint (in the form of sudden cardiac death or heart 
attack in patients), included in subsequent editions of the 
ESC guidelines on the treatment of stable coronary heart 
disease.
In a later meta-analysis of Antiplatelet Triallists’ Collabo-
ration (17,000 patients, Table 1), it was demonstrated that 
patients with high cardiovascular risk receiving ASA showed 
a 25% reduction in the risk of cardiovascular events (from 
8.2% to 6.7% per year). The risk of stroke was reduced from 
2.6% per year to 2.1% per year, and the risk of coronary 
complications from 5.3% per year to 4.3% per year [5]. 
Despite a simultaneous increase in the risk of significant 
bleeding, a reduction in overall mortality of 10% was con-
firmed. These guidelines explicitly recommend the use of 
ASA after acute coronary syndrome and ischaemic stroke 
or transient ischaemic episode, with the highest class of 
IA recommendations, permanently. In many situations, 
ASA is part of double or triple anticoagulant therapy, most 
often used in recent acute coronary syndrome or arterial 
stent surgery. This vast area of medicine goes beyond the 
scope of this study, but is discussed in detail in the recently 
developed ESC Expert Document [6].
A further recommendation to use ASA in patients with 
known ischaemic heart disease after a stroke or transient 
ischaemic attack (TIA) and with symptomatic peripheral 
vascular disease, are the American Heart Association/ 
/American College of Cardiology Foundation (AHA/ACCF) 
2011 guidelines regarding secondary prevention and risk-
-reducing therapies in patients with coronary artery disease 
and other atherosclerotic vascular disease. These state 
that in patients with any type of coronary artery disease, 
especially after a heart attack, or in patients who have had 
cerebrovascular incidents and have no contraindications, 
chronic ASA therapy at a dose of 75–162 mg/day should 
be initiated and continued.
However, there are serious doubts regarding primary 
prevention. The systematic review cited in the European do-
cument, covering six studies including a total of 95,000 pa-
tients without overt cardiovascular and cerebrovascular 
disease using chronic ASA versus placebo did not produce 
any revelations. Reducing the risk of cardiovascular com-
plications from 0.57% per year to 0.51% per year with a si-
multaneous increase in the risk of major extracranial and 
gastrointestinal bleeding by 0.03% per year, and no change 
in the risk of cardiovascular mortality, constitute the basis 
for a contraindication to the chronic use of ASA in people 
without atherosclerosis and people with low cardiovascular 
risk (class IIIB). These findings were confirmed in the latest, 
even more extensive, meta-analysis (157,248 patients): 
again, ASA used in primary prevention was proved to redu-
ce the risk of heart attack by 18%, with no effect on total 
mortality at an average follow-up of 6.6 years, due to an 
increase in the frequency of clinically significant bleeding 
by 47% (intracranial — 33%) [7].
A slightly different position was presented by the 
authors of the US Prevention Service Task Force guidelines 
[8] regarding the use of ASA in primary prevention, in op-
position to European guidelines. The US document admits 
two groups of patients for whom ASA is to be considered, 
including one group in which it is in fact recommended. 
These are people who meet the following criteria: age 
Table 1. A shift in risk of major clinical events during chronic use of acetylsalicylic acid (ASA) — Antithrombotic Triallists Collaboration 
2009 meta-analysis (modified based on [5])
Clinical event Absolute annual risk difference when using ASA vs. placebo (Δ%/year)
Primary prevention 
(n = 660,000 patients × years)
Secondary prevention 
(n = 43,000 patients × years)
Serious coronary event –0.06 –1.00
Non-fatal heart attack –0.05 –0.66
Death from coronary event –0.01 –0.34
Stroke –0.01 –0.46
Haemorrhagic stroke –0.01 Data difficult to compile
Death from cardiovascular reasons –0.01 –0.29
Cardiovascular event –0.07 –1.49
Serious extracranial haemorrhage +0.03 Data difficult to compile
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In summary, optimal strategies for the prophylactic use 
of ASA end up with an accurate identification of populations 
in which the reduction of the risk of thrombotic compli-
cations connected to atherosclerosis (ASA’s protective 
effect on myocardial infarction is indisputable) exceeds 
the relatively constant values of excessive, dangerous 
bleeding. Current data indicates only the group of secon-
dary prevention (after a heart attack or stroke) as having 
clear benefits from preventive ASA therapy.
Resistance to ASA — failure to prevent  
(im)possible to overcome?
Another important element of ASA pharmacotherapy is 
the phenomenon of resistance, in other words failure to 
achieve an adequate clinical or pharmacological response 
to typical doses of the drug. The phenomenon of resistance 
has been known since the mid-1990s when [12] when loss 
of full response to treatment was reported in up to a third 
of patients, while after increasing the dose to 1.3 g/day 
resistance remained in 8% of patients. The basic problem 
remains to define whether resistance is actually increa-
sing, or whether there is an individual non-response to 
ASA a priori.
Gum et al. [13], in a study published in 2006, decided 
to verify the prognostic consequences of ASA resistance. 
Aspirin resistance was found in 5.2% of 326 patients 
with stable cardiovascular disease receiving ASA at 
325 mg/day. The risk of a composite endpoint was 
3.12 times higher in the population resistant to ASA over 
a 2-year follow-up period. Therefore, this phenomenon 
is clinically significant. In a population of patients with 
coronary artery disease qualified for revascularisation in 
our own clinic, the frequency of incorrect response to ASA 
was about 13% [14]. The study examined whether the 
dose increase would ensure adequate platelet response, 
and attempted to identify predictors of ASA resistance. 
In the Lodz study, the main risk factors for resistance 
were male sex, high platelet count, and leucocytosis. 
In view of breaking the resistance in 62.5% of patients 
after doubling the dose to 150 mg/day (more often in 
men and in patients with moderately exceeded platelet 
function indices), it seems reasonable to personalise 
the dose in relation to specific conditions in individual 
patients, and the dose of 75 mg/day in the entire Polish 
population cannot be considered sufficient. The authors 
of the German BOCLA-Plan (the BOchum CLopidogrel 
and Aspirin Plan) study [15] proved that in a group of 
504 patients treated with ASA, 80.6% of patients re-
sponded to the 100 mg/day dose, while the remaining 
19.4% of patients responded to higher doses: 18.35% 
responded to a 300 mg/day dose, and 1.05% respon-
ded to a 500 mg/day dose. Importantly, no definitive 
resistance was found at all.
50–59 years who have a low risk of bleeding, an expected 
survival of at least 10 years, an expected duration of taking 
ASA of not less than 10 years, and a cardiovascular risk 
calculated using ASCVD (Atherosclerotic Cardiovascular 
Disease) of not lower than 10%. They are recommended to 
use ASA in a dose of 75–150 mg/day. For people who meet 
the other criteria, but who are a decade older (60–69 ye-
ars), the inclusion of ASA may be considered according 
to the US guidelines. The effects of such proceedings in 
a group of 10,000 patients would be to prevent 225 heart 
attacks, 84 ischaemic strokes and 139 bowel cancers, but 
at the expense of 284 serious extracranial bleedings and 
23 haemorrhagic strokes.
Given the results of the latest ASCEND (A Study of Car-
diovascular Events iN Diabetes) [9] and ARRIVE [10] studies 
published during the ESC 2018 Congress in Munich, the 
issue of primary prevention recommendations is becoming 
even more distant. The ARRIVE study was designed to study 
the effect of taking 100 mg/day ASA compared to placebo 
in a group of 12,500 patients with intermediate cardiova-
scular risk (defined as 10–20% in 10 years; actual risk was 
approximately 8.5% in 10 years) but no diabetes or known 
cardiovascular disease. Male patients had to be at least 
55 years old and had to have two additional risk factors, 
women had to be at least 60 years-old and to have three 
risk factors. The use of ASA was not found to significantly 
change the risk of cardiovascular events, while the risk of 
gastrointestinal bleeding is significantly increased (from 
0.5% to 1%/year); severe bleeding occurred in only two 
patients in the placebo group and in four in the ASA group. 
The disadvantages of the study include an underestimation 
of the level of cardiovascular risk, as well as problems with 
the co-operation of patients during the trial patients who 
have taken at least 60% of doses correctly have been shown 
to have a 47% reduction in the risk of heart attack typical 
of other studies using ASA.
The impact of taking 100 mg/day of ASA for more 
than seven years compared to taking placebo in a group 
of nearly 15,500 was analysed in the ASCEND study [7] 
with known diabetes but no known cardiovascular disease. 
A statistically significant reduction in the risk of cardiova-
scular events by as much as 12% was overshadowed by 
the fact that the risk of major bleeding (usually from the 
gastrointestinal tract) increased by as much as 29%. The 
potential beneficial preventive effect was therefore almost 
completely counteracted by the side effects.
Similarly, the identification of candidates for ASA as part 
of primary prevention based on age did not meet expec-
tations — the ASPREE study (ASPirin in the Prevention of 
Events in the Elderly) [11] conducted in a population of fit 
seniors (median 74 years) focused on reducing the risk of 
death, dementia or permanent disability. Protective featu-
res were not reported, although an expected 38% increase 
in the incidence of haemorrhagic incidents was.
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This confirms the validity of dose escalation in patients 
at high risk for atherosclerosis. In the BOCLA study, the 
risk factors were a history of acute coronary syndrome, 
elevated troponin levels, diabetes, high platelet counts, 
elevated C-reactive protein (CRP), glycated haemoglobin 
(HbA1c), creatinine and haemoglobin, and proven poor 
response to clopidogrel.
The BOCLA study sheds new light on the problem of 
resistance; its results suggest that individual non-response 
to ASA is not a common cause. It seems that, as in the case 
of other preventive therapies, an important reason may be 
a failure to comply with medical instructions by a significant 
group of patients. Even under supervised clinical trials, as 
many as 40% of patients are found not to be taking the 
drug as prescribed after several years.
Improving patient co-operation in the field 
of preventive therapies
Prevention of cardiovascular incidents can only be truly 
effective when it is uninterrupted. Differences in the per-
ception of the benefits and losses of treatment may occur 
at the professional level — EUROASPIRE registers IV and V 
indicate that 7% of patients with coronary artery disease 
do not take ASA, and surely the patient’s perspective on 
treatment neccessity differs from the doctor’s assessment.
The problem is not just ASA; it is estimated that insuffi-
cient therapeutic compliance is responsible for approxima-
tely 10% of acute circulatory complications in Europe [16]. 
Quite often, discontinuation of ASA therapy may also have 
an iatrogenic background, and one of the main causes is 
gastrointestinal side effects. These are much more often 
of a dyspeptic nature, rather than major bleeding. The 
European guidelines for the prevention of cardiovascular 
diseases explicitly recommend maximum simplification of 
treatment with active surveillance measures, assessing 
the level of patient co-operation, and identifying failures; it 
is also recommended to use tablets containing more than 
one active ingredient.
Risk factors for the significant problem of insufficient 
persistence in the use of preventive therapies seem to 
be indications for treatment that do not cause subjective 
discomfort, as well as excessive complexity of therapy 
causing adverse effects. An online survey published in 
2011 found that out of 1,007 respondents, among whom 
67% took 81 mg of ASA, as many as 88% felt heartburn or 
reflux, 15% missed doses due to combinations with other 
drugs or just gastro-oesophageal problems, and as many 
as 19% made interruptions in therapy due to dyspeptic 
symptoms [17]. This resulted in the insufficient co-operation 
of 28% of respondents.
Tolerance for chronic ASA treatment varies from per-
son to person, but some side effects are quite common. 
In CAPRIE (Clopidogrel vs. Aspirin in Patients at Risk of 
Ischaemic Events), ASA at a dose of 325 mg/day caused 
gastrointestinal bleeding in 2.7% of patients, gastrointesti-
nal ulceration in 1.2%, and indigestion, nausea or vomiting 
in up to 17.6%. Ulcers and bleeding after ASA are mainly 
caused by inhibition of prostaglandin’s protective effect 
on the gastric mucosa, but also by a decrease in gastro-
intestinal pH and, of course, antiplatelet effect (Figure 1).
One way to improve ASA tolerance is to modify the tab-
let form, and enteric-coated tablets are commonly used. 
These improve the tolerance of the therapy but they are not 
a complete solution as they protect primarily the stomach, 
but not the intestine. Gastro-resistant tablets compared 
to buffered tablets are associated with a greater need for 
proton pump inhibitors (PPIs) or H2 antagonists (14.4% vs. 
25.4%). Buffered tablets were also characterised by a 39% 
lower number of ulcers and a 21% reduction of blood in 
the stool after 12 months of therapy — this form of galling 
is not widely available.
From the perspective of gastrointestinal complications, 
the preventive use of PPI also seems beneficial. In American 
and Polish guidelines, it is recommended that patients 
with indications for antiplatelet therapy have their gastro-
intestinal risk assessed. This is elevated in patients with 
a history of complicated or non-complicated peptic ulcer 
disease (in this group of patients it is recommended to 
eradicate Helicobacter pylori in case of confirmed status 
of the carrier), a history of gastrointestinal bleeding during 
dual antiplatelet therapy, as well as those treated with oral 
anticoagulants (OAC). PPI should be included in the high-
-risk group. Patients who do not meet the above-mentioned 
criteria should also be evaluated for the following risk fac-
tors: age 60 and over, corticosteroid therapy, dyspepsia, 
or gastrointestinal reflux symptoms. In these patients, the 
inclusion of PPI also seems to be the optimal solution. It 
has been estimated that a combination of ASA and PPI 
reduces the risk of gastrointestinal bleeding over a lifetime 
from 7.2% to 3.4%, increases the adherence rate from 71% 
to 74%, reduces the incidence of recurrent heart attack by 
26,100 patients, extends life by an average of 38 days, and 
reduces the total cost of treating patients by $19,000 over 
a year. Unfortunately, PPI does not show an additive effect 
on ASA, and its protective effect is limited only to the sto-
mach. In addition, therapeutic compliance with PPI is also 
not ideal. However, the coatings of the gastro-resistant 
tablets may affect the effectiveness of the medicine. 
An important observation concerns the identification of 
pseudo-resistant patients due to the type of gastro-resistant 
tablet used so far. Among type 2 diabetic patients using 
ASA 325 mg/day, the percentage of people whose throm-
boxane activity remained dangerously high was the highest 
in the group of enteric-coated tablets (52.8%) compared to 
the group receiving lipid tablets (8.1%) or ordinary tablets 
(15.8%) [18]. Other studies have provided evidence of the 
effect of enteric coating on the bioavailability of ASA and 
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its significant negative role in limiting the preventive effect 
of the drug [19].
Recently, combinations of ASA and glycine have also 
appeared (tablet buffered on the Polish market containing 
100 mg ASA with 40 mg glycine). The combination of ASA 
with glycine results from the fact that it is of key importan-
ce in the lining of the gastrointestinal tract formation, as 
it is significantly involved in the synthesis of collagen and 
gelatin. In addition, it has anti-inflammatory, cytoprotecti-
ve and immunomodulatory properties. It reduces tissue 
ischaemia caused by haemorrhagic shock, stimulates 
protein synthesis in the cells of the gastrointestinal tract, 
and protects them from oxidative stress. Animal studies 
have also found its vasodilatory effect and effect on gastric 
acid secretion, as well as on the thickness of the walls and 
mucous membrane of the gastrointestinal tract. Overall, it 
protects against stress ulcers.
It also turns out that this amino acid increases the 
solubility of ASA and facilitates its absorption, prevents 
the irritating effect on the mucosa and supports the re-
generation of the digestive tract. In 2014, Murtaza et al. 
[20] conducted studies on increasing the solubility and 
absorption of ASA in assistance of various amino acids. 
The results were promising, as significantly higher solu-
bility was observed for most of the tested amino acids. 
The authors suggested that administration of ASA with 
free amino acids or protein meals may significantly affect 
drug absorption. Müller et al. [21] compared the effect 
of 500 mg ASA and the same dose of ASA with 250 mg 
glycine on gastric and duodenal mucosa in 20 healthy 
volunteers during four weeks of therapy. Nine out of 
10 patients reported distressing dyspeptic symptoms in 
the group receiving ASA only, while none did in the group 
treated with glycine. There is also clinical evidence to 
improve the tolerance of ASA administered with glycine: 
Kusche et al. [22] sequentially compared the observa-
tions of patients undergoing long-term ASA therapy at 
a dose of 50–100 mg/day to the subsequent inclusion 
Figure 1. Inhibition of cyclooxygenase 1 (COX-1) by acetylsalicylic acid (ASA) and gastrointestinal adverse reactions
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of combination therapy with ASA and glycine after a mo-
notherapy period of at least one month. Tolerance was 
assessed on the basis of an interview and compared to 
previous observations of the subjects.
It turned out that the percentage of patients without 
gastrointestinal symptoms increased from 28.2% to 60.6%. 
The percentage of patients with recurrent stomach discom-
fort during therapy decreased from 8.5% to 0.5%. Based on 
these results, it was concluded that the addition of glycine 
to standard therapy not only increases the bioavailability 
of ASA, allowing the patient to benefit fully from the ad-
ministered dose, but also at the same time it significantly 
improves ASA tolerance by reducing its gastrointestinal 
adverse effects. Such management also allows for potential 
reduction or withdrawal from PPI therapy, thanks to which 
their various adverse effects can be avoided.
Conclusions
ASA does not lose its relevance as primary therapy in the 
secondary prevention of cardiovascular complications and 
strokes. According to the current consensus in Europe is 
not recommended for primary prevention because of the 
increased risk of haemorrhagic complications. The clinical 
effectiveness of the drug is influenced by its tolerance 
profile, with dominant uncomfortable symptoms of gastro-
intestinal mucosal irritation. Some patients may need PPI 
administration. In addition to widely used, but not fully 
enteric, neutral forms of the drug, a new proposal to solve 
the problem of intolerance is a tablet containing a combi-
nation of ASA in a dose of 100 mg and 40 mg of glycine. 
This is an interesting alternative, improving the tolerance 
profile of the drug on the part of the gastrointestinal tract 
without increasing costs and the number of tablets taken, 
which may translate into better therapeutic compliance, 
and therefore better long-term effects in preventing serious 
cardiovascular incidents.
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Streszczenie
W niniejszym opracowaniu podsumowano aktualne zalecenia dotyczące właściwości przeciwpłytkowych oraz wskazań 
do profilaktycznego stosowania małych dawek kwasu acetylosalicylowego (ASA). Omówiono wyniki najnowszych badań 
dotyczących przede wszystkim prewencji pierwotnej, optymalnego dawkowania w kontekście zagadnienia aspiryno-
oporności oraz możliwości poprawy długoterminowej współpracy pacjentów wymagających stosowania ASA. Omówiono 
również sposoby zapobiegania stosunkowo częstemu problemowi nietolerancji leku ze strony przewodu pokarmowego.
Słowa kluczowe: ASA, miażdżyca, farmakoterapia, choroba niedokrwienna, bezpieczeństwo
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